ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.015,83
-0,03%
S&P 500
5.431,60
0,00%
Dow Jones
38.589,16
0,00%
Euro vs US Dollar
1,07093
0,07%
Bitcoin
65.480,93
-1,74%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Neumora Therapeutics Inc (NMRA)

  7. Neumora Therapeutics Inc (NMRA) News

NMRA

Neumora Therapeutics (NMRA)

Neumora Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NMRA
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
14/06/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
14/05/202413h00GlobeNewswire Inc.Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar DepressionNASDAQ:NMRANeumora Therapeutics Inc
07/05/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NMRANeumora Therapeutics Inc
07/05/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
07/05/202413h00GlobeNewswire Inc.Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
06/05/202413h00GlobeNewswire Inc.Neumora Therapeutics to Participate in Upcoming Conferences in MayNASDAQ:NMRANeumora Therapeutics Inc
15/04/202412h30GlobeNewswire Inc.Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 StudyNASDAQ:NMRANeumora Therapeutics Inc
13/03/202412h00GlobeNewswire Inc.Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS DaysNASDAQ:NMRANeumora Therapeutics Inc
07/03/202422h34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NMRANeumora Therapeutics Inc
07/03/202413h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
07/03/202413h00GlobeNewswire Inc.Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
16/02/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
16/02/202422h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
16/02/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
16/02/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
22/01/202413h00GlobeNewswire Inc.Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial OfficerNASDAQ:NMRANeumora Therapeutics Inc
08/01/202414h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
02/01/202413h00GlobeNewswire Inc.Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NMRANeumora Therapeutics Inc
15/12/202323h06Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NMRANeumora Therapeutics Inc
12/12/202313h00GlobeNewswire Inc.Neumora Therapeutics Appoints Jason Duncan as Chief Legal OfficerNASDAQ:NMRANeumora Therapeutics Inc
28/11/202322h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
27/11/202313h00GlobeNewswire Inc.Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical StudyNASDAQ:NMRANeumora Therapeutics Inc
01/11/202321h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NMRANeumora Therapeutics Inc
01/11/202321h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
01/11/202312h00GlobeNewswire Inc.Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
30/10/202312h00GlobeNewswire Inc.Neumora Therapeutics to Participate in Upcoming Conferences in NovemberNASDAQ:NMRANeumora Therapeutics Inc
10/10/202313h00GlobeNewswire Inc.Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and DevelopmentNASDAQ:NMRANeumora Therapeutics Inc
20/09/202300h51KR Market News인스타카트, 나스닥 데뷔로 주가는 12% 상승NASDAQ:NMRANeumora Therapeutics Inc
15/09/202302h49GlobeNewswire Inc.Neumora Therapeutics Announces Pricing of Initial Public OfferingNASDAQ:NMRANeumora Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NMRA

Kürzlich von Ihnen besucht

USOTC
BASFY
BASF (QX)
DBI
TDXP
Tec DAX
CCOM
SILVER
SILVER
TG
BAS
BASF
COIN
ETHUSD
Ethereum
TG
MBG
MercedesBenz
NASDAQ
NVDA
NVIDIA
FX
EURUSD
Euro vs US Dollar
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
NOV
Novo Nordisk
NYSE
XOM
Exxon Mobil
TG
BAYN
Bayer
TG
LHA
Deutsche Lufthansa
AMEX
XLE
Energy Select Sector SPDR
CCOM
US30
US 30
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten